Micafungin: A review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections

Drugs

Volumn 68, Issue 15, 2008, Pages 2225-2255

  Cross, Sarah A ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis drug evaluations; Candidiasis, prevention; Candidiasis, treatment; Micafungin, general

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOSPORIN; FLUCONAZOLE; FUNGARD; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; PREDNISOLONE; RAPAMYCIN; RIFAMPICIN; RITONAVIR; TACROLIMUS; UNCLASSIFIED DRUG; VORICONAZOLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAPHYLAXIS; ANTIFUNGAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG USE; ESOPHAGUS CANDIDIASIS; FACE EDEMA; FEVER; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPOKALEMIA; INFECTION PREVENTION; INJECTION SITE REACTION; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FAILURE; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PHLEBITIS; PRURITUS; RASH; REVIEW; RIGOR; SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; UREA BLOOD LEVEL; VOMITING;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; DRUG THERAPY, COMBINATION; ECHINOCANDINS; ESOPHAGEAL DISEASES; HIV INFECTIONS; HUMANS; LIPOPEPTIDES;

CANDIDA; FUNGI;

EID: 53549117142     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868150-00010     Document Type: Review

References (121)

1. Sable CA, Strohmaier KM, Chodakewitz JA. Advances in antifungal therapy. Annu Rev Med 2008; 59: 361-79
2. Juang P. Update on new antifungal therapy. AACN Adv Crit Care 2007; 18 (3): 253-60
3. Ullmann AJ, Cornely OA. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 2006; 19 (6): 571-6
4. van Burik JA. Role of new antifungal agents in prophylaxis of mycoses in high risk patients. Curr Opin Infect Dis 2005; 18 (6): 479-83
5. Bennett JE. Echinocandins for candidemia in adults without neutropenia. New Engl J Med 2006; 355 (11): 1154-9
6. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366: 1013-25
7. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006; 20 (3): 485-506
8. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20 (1): 133-63
9. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000; 30: 653-7
10. Jarvis B, Figgitt DP, Scott LJ. Micafungin. Drugs 2004; 64 (9): 969-82
11. Carter NJ, Keating GM. Micafungin: a review of its use in paediatric patients for the treatment of Candidaemia and invasive infections, and as prophylaxis against invasive Candidia spp. infections in neutropenia. Pediatric Drugs. In press
12. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42 (8): 1171-8
13. Matsue K, Uryu H, Koseki M, et al. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006; 42 (6): 753-7
14. Ikeda F, Tanaka S, Ohki H, et al. Role of micafungin in the antifungal armamentarium. Curr Med Chem 2007; 14 (11): 1263-75
15. Astellas Pharma US. Mycamine (micafungin sodium) for injection: US prescribing information [online]. Available from URL: http://www.astellas.us/ docs/mycamine-ic.xml [Accessed 2008 Jun 3]
16. Astellas Pharma Inc. Fungard® 25mg for infusion, Fungard® 50mg for infusion, Fungard® 75mg for infusion (micafungin sodium for injection): Japanese prescribing information [online]. Available from URL: http://ns.e-search.ne.jp/~jpr/ [Accessed 2007 Jun 8]
17. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard M27-A3. 3rd ed. Wayne (PA): Clinical and Laboratory Standards Institute, 2008; 28 (14): 1-25
18. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: third informational supplement. Wayne (PA): National Committee for Clinical Laboratory Standards, 2008; 28 (15): 1-19
19. Pfaller MA, Boyken I, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46 (1): 150-6
20. Dannaoui E, Lortholary O, Raoux D, et al. In vitro activity of caspofungin and micafungin against 1038 yeasts isolates from France by EUCAST reference method [abstract no. P1974 plus poster]. 17th European Congress of Clinical Microbiology and Infectious Diseases and the 25th International Congress of Chemotherapy; 2007 Mar 31-Apr 3; Munich
21. Takakura S, Fujihara N, Saito T, et al. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 2004; 53 (2): 283-9
22. Müller F-MC, Kurzai O, Hacker J, et al. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolated of Candida dubliniensis. J Antimicrob Chemother 2001; 48: 713-5
23. Rodriguez-Tudela JL, Barchiesi F, Bille J, et al. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. EUCAST discussion document E.Dis 7.1. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). Clin Microbiol Infect 2003 Aug; 9 (8): 1-8
24. Paderu P, Garcia-Effron G, Balashov S, et al. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007; 51 (6): 2253-6
25. Mochizuki N, Aibiki M, Matsumoto Y. Evaluation of micafungin activity in serum, including serum synergism [abstract no. M-1598]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sept 27-30; San Francisco (CA), 423
26. Cantón E, Pemán J, Sastre M, et al. Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Antimicrob Agents Chemother 2006; 50 (8): 2829-32
27. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44 (1): 57-62
28. Ernst EJ, Roling EE, Petzold CR, et al. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002; 46 (12): 3846-53
29. Mochizuki N, Ishikawa J, Matsumoto Y, et al. Evaluation of micafungin antifungal activities in patient serum [abstract no. M-1818]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17-20; Chicago (IL)
30. Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46 (6): 1773-80
31. Seidler M, Salvenmoser S, Muller F-MC. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections. Int J Antimicrob Agents 2006; 28 (6): 568-73
32. Manavathu EK, Ramesh MS, Baskaran I, et al. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004; 53 (2): 386-9
33. Heyn K, Tredup A, Salvenmoser S, et al. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005; 49 (12): 5157-9
34. Rodriguez MM, Ruiz M, Pastor FJ, et al. In vitro interaction of micafungin and fluconazole against Candida [letter]. J Antimicrob Chemother. Epub 2007 May 24
35. Marine M, Serena C, Pastor J, et al. In vitro activity of micafungin combined with itraconazole against Candidia spp. Int J Antimicrob Agents 2007; 30 (5): 463-5
36. Mariné M, Serena C, Pastor FJ, et al. Combined antifungal therapy in a murine infection by Candida glabrata. J Antimicrob Chemother 2006; 58 (6): 1295-8
37. Olson JA, Adler-Moore JP, Smith PJ, et al. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005; 49 (12): 4895-902
38. Park S, Kelly R, Nielsen Kahn J., et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49 (8): 3264-73
39. Groll AH, Walsh TJ. FK-463 Fujisawa Pharmaceutical Co Ltd. Curr Opin Anti Infect Drugs 2000; 2 (4): 405-12
40. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of Candida spp. to anidulafungin, caspofungin and micafungin: six years of global surveillance [abstract no. M-552]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17-20; Chicago (IL)
41. Pfaller MA, Diekema DJ, Gibbs DL, et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001-2005. J Clin Microbiol 2008; 46: 515-21
42. Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46 (3): 842-9
43. Baixench MT, Aoun N, Desnos-Ollivier M, et al. Acquired resistance to echinocandins in. J Antimicrob Chemother 2007; 59 (6): 1076-83
44. Laverdière M, Lalonde RG, Baril JG, et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57: 705-8
45. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50 (7): 2522-4
46. Wierman M, Obeid K, Baxa D. Emergence of C. glabrata isolates with reduced susceptibility to caspofungin and micafungin, but not anidulafungin [abstract no. M-512]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17-20; Chicago (IL)
47. Schuetzer-Muehlbauer M, Willinger B, Krapf G, et al. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol 2003; 48 (1): 225-35
48. Niimi K, Maki K, Ikeda F, et al. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob Agents Chemother 2006; 50 (4): 1148-55
49. McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005; 65 (14): 2049-68
50. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004 Sep; 48 (9): 3407-11
51. Chamilos G, Lewis RE, Albert N, et al. The paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 2007 Jun; 51 (6): 2257-9
52. Jacobsen MD, Whyte JA, Odds FC. Candida albicans and Candida dubliniensis respond differently to echinocandin antitherapy fungal agents in vitro. Antimicrob Agents Chemother 2007 May; 51 (5): 1882-4
53. Douglas CM, D'Ippolito JA, Shei GJ, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997; 41 (11): 2471-9
54. Richards TS, Oliver BG, White TC. Micafungin activity against Candidia albicans with diverse azole resistance phenotypes. J Antimicrob Chemother 2008; 62 (2): 349-55
55. Messer SA, Diekema DJ, Boyken L, et al. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 2006; 44 (2): 324-6
56. Melkusova S, Bujdakova H, Vollekova A, et al. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis. Pharmazie 2004; 59 (7): 573-4
57. Borg-von Zepelin M, Zaschke K, Gross U, et al. Effect of micafungin (FK463) on Candida albicans adherence to epithelial cells. Chemotherapy 2002; 48 (3): 148-53
58. Gil-Lamaignere C, Salvenmoser S, Hess R, et al. Micafungin enhances neutrophil fungicidal functions against Candida pseudohyphae. Antimicrob Agents Chemother 2004; 48 (7): 2730-2
59. Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005; 45 (10): 1145-52
60. Azuma J, Yamamoto I, Ogura M, et al. Phase I study of FK463, a new antifungal agent, in healthy adult male volunteers [abstract no. F-146]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego (CA), 269
61. 14C-FK463, a novel echinocandin antifungal, in male volunteers [abstract no. 17]. J Clin Pharmacol 2000; 40 (9): 1048
62. Hebert MF, Blough DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45 (9): 1018-24
63. Undre N, Stevenson P, Wilbraham D. Amphotericin B does not affect the pharmacokinetics of micafungin (FK463) [abstract no. P971 plus poster]. 17th European Congress of Clinical Microbiology and Infectious Diseases and the 25th International Congress of Chemotherapy; 2007 Mar 31-Apr 3; Munich
64. Undre N, Stevenson P, Brooks A. Itraconazole does not affect the pharmacokinetics of micafungin (FK463) [abstract no. P970 plus poster]. 17th European Congress of Clinical Microbiology and Infectious Diseases and the 25th International Congress of Chemotherapy; 2007 Mar 31-Apr 3; Munich
65. Hebert MF, Townsend RW, Austin S, et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45 (8): 954-60
66. Keirns J, Sawamoto T, Holum M, et al. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother 2007; 51 (2): 787-90
67. Mukai T, Ohkuma T, Nakahara K, et al. Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and nonelderly subjects [abstract no. A-30]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago (IL), 5
68. Townsend R, Bekersky I, Buell DN, et al. Pharmacokinetic (PK) evaluation of echinocandin FK463 in pediatric and adult patients [abstract no. 024]. 11th Focus on Fungal Infections Meeting; 2001 Mar 14-16; Washington, DC
69. Shimoeda S, Ohta S, Kobayashi H, et al. Analysis of the blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus. Biol Pharm Bull 2005; 28 (3): 477-80
70. Tabata K, Katashima M, Kawamura A, et al. Pharmacokinetics- pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis. Eur J Drug Metab Pharmacokinet 2006; 31 (2): 123-8
71. Mochizuki N, Matsumoto K, Ohno K, et al. Effects of hepatic CYP3A4 activity on disposition of micafungin in liver transplant recipients with markedly small-for-size grafts. Transplant Proc 2006; 38 (10): 3649-50
72. Narumi S, Hakamada K, Toyoki Y, et al. Influence of antifungal agents on trough level of tacrolimus [abstract no. 1247]. Am J Transplant 2005; 5 Suppl. 11: 474
73. Kishino S, Ohno K, Shimamura T, et al. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transplant 2004; 18 (6): 676-80
74. Okugawa S, Ota Y, Tatsuno K, et al. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. Scand J Infect Dis 2007; 39 (4): 344-6
75. European Medicines Agency. Mycamine: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ mycamine/H-734-PI-en.pdf [Accessed 2008 May 12]
76. Hirata K, Aoyama T, Matsumoto Y, et al. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi 2007; 127 (5): 897-901
77. Kuse E, Demeyer I, Stevenson P, et al. Pharmacokinetics of micafungin in adult patients with invasive candidiasis and candidaemia [abstract no. A-770]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17-20; Chicago (IL)
78. Groll AH, Mickiene D, Petraitis V, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001; 45 (12): 3322-7
79. Niwa T, Yokota Y, Tokunaga A, et al. Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol Pharm Bull 2004; 27 (7): 1154-6
80. Joseph JM, Jain R, Danziger LH. Micafungin: a new echinocandin antifungal. Pharmacotherapy 2007; 27 (1): 53-67
81. Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005; 49 (4): 1331-6
82. Sakaeda T, Iwaki K, Kakumoto M, et al. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 2005; 57 (6): 759-64
83. Undre NA, Stevenson P, Amakye DD. Rifampicin and ritonavir do not affect the pharmacokinetics of micafungin (FK463), an echinocandin antifungal [abstract no. P1037]. Clin Microbiol Infect 2004; 10 Suppl. 3: 279
84. Pappas PG, Rotstein CMF, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007 Oct 1; 45: 883-93
85. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 2007; 369 (9572): 1519-27
86. Cornely OA, Sidhu M, Odeyemi I, et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008; 24 (6): 1743-53
87. Eiland EH, Hassoun A, English T. Points of concern related to the micafungin versus caspofungin trial [letter]. Clin Infect Dis 2008; 46 (4): 640-1
88. de Wet NTE, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21 (7): 899-907
89. European Medicines Agency. Assessment report for mycamine (EMEA/H/C/000734) [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/mycamine/H-734-en6.pdf [Accessed 2008 Jul 2]
90. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39 (6): 842-9
91. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39 (10): 1407-16
92. Tortorano AM, Kibbler C, Peman J, et al. Candidemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006; 27 (5): 359-66
93. European Medicines Agency. Cancidas: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ cancidas/224601en1.pdf [Accessed 2007 Jul 24]
94. European Medicines Agency. ECALTA: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ ecalta/H-788-en1.pdf [Accessed 2008 Jul 21]
95. Pfizer Limited. Difulcan™ capsules 50mg and 200mg, powder for oral suspension 50mg/ml and 200mg/ml, intravenous infusion 2mg/ml [online]. Available from URL: http://www.emc.medicines.org.uk/emc/assets/c/html/displayDocPrinter- Friendly.asp?documentid=1459 [Accessed 2007 Aug 1]
96. Janssen-Cilag Ltd. Sporanox I.V. 10mg/ml concentrate and solvent for solution for infusion: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk/emc/assets/c/html/displayDocPrinter- Friendly.asp?documentid=2489 [Accessed 2007 Jul 27]
97. Janssen-Cilag Ltd. Sporanox capsules: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk/emc/assets/c/html/ displayDocPrinter-Friendly.asp?documentid=7395 [Accessed 2007 Jul 27]
98. European Medicines Agency. VFEND: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ vfend/404901en1.pdf [Accessed 2007 Jul 27]
99. European Medicines Agency. Posaconazole: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/posaconazole/H-611-en1.pdf [Accessed 2008 Jul 20]
100. E. R. Squibb & Sons Limited. Fungizone intravenous: summary of product characteristics [online]. Available from URL: http://www.emc.medicines. org.uk/emc/assets/c/html/displayDoc-PrinterFriendly.asp?documentid=18414 [Accessed 2007 Jul 24]
101. Gilead Sciences International Limited. Ambisome: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk/ emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=1236 [Accessed 2007 Aug 1]
102. Cephalon Limited. Abelcet®: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk/emc/assets/c/html/ displayDocPrinter-Friendly.asp?documentid=2133 [Accessed 2007 Aug 2]
103. Beacon Pharmaceuticals. Amphocil™ 100mg: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk/ emc/assets/c/html/displayDoc-PrinterFriendly.asp?documentid=559 [Accessed 2007 Aug 1]
104. Valent Pharmaceuticals Ltd. Ancotil 2.5g/250ml solution for infusion: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp? documentid=6215 [Accessed 2007 Jul 27]
105. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34 (3): 857-63
106. Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. British Society for Medical Mycology. Lancet Infect Dis 2003; 3 (4): 230-40
107. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38 (2): 161-89
108. Herbrecht R, Flückiger U, Gachot B, et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Suppl 2007; 5: 49-59
109. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer 2007; 5 Suppl.: 32-42
110. Maertens JA, Frère P, Lass-Flörl C, et al. Primary antifungal prophylaxis in leukemia patients. Eur J Cancer Suppl 2007; 5: 43-8
111. British Committee for Standards in Haematology. Guidelines on the management of invasive fungal infection during therapy for haematological malignancy [online]. Available from URL: http://www.bcshguidelines.com/pdf/ IFI_therapy.pdf [Accessed 2008 Jun 30]
112. Spellberg BJ, Filler SG, Edwards Jr JE. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42: 244-51
113. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78
114. Pfzier Inc. Eraxis™ (anidulafungin) for injection: US prescribing information [online]. Available from URL: http://www.pfizer.com/pzier/download/ uspi_eraxis.pdf [Accessed 2007 Aug 2]
115. Rapp RP. Changing strategies for the management of invasive fungal infections. Pharmacotherapy 2004; 24 (2 Pt 2): 4-28
116. Ullmann AJ, Sanz MA, Tramarin A, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006; 43: 29-38
117. Enzon Pharmaceuticals. Abelcet®: US prescribing information [online]. Available from URL: http://www.enzon.com/products/abelcet/Abelcet-PI.pdf [Accessed 2007 Aug 2]
118. Slavin MA, Szer J, Grigg AP, et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Int Med J 2004; 34: 192-200
119. Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges. Pharmacotherapy 2003; 23 (11): 1441-62
120. Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43 Suppl. 1: 28-39
121. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007 Mar; 27 (3): 369-88